Selecting Aβ isoforms for an Alzheimer's disease cerebrospinal fluid biomarker panel.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Biomarkers in Medicine

• Publication date

  2017-01-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/bmm-2016-0276PMID 28111962
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CSF Aβ1-42 - an excellent but complicated Alzheimer's biomarker - a route to standardisation.

  2017cited by this paper
• CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease

  2016cited by this paper
• Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor

  2016cited by this paper
• Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study

  2016cited by this paper
• Amyloid mis-metabolism in idiopathic normal pressure hydrocephalus

  2016cited by this paper
• Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer’s Disease

  2016cited by this paper
• CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.

  2016cited by this paper
• The Gothenburg MCI study: Design and distribution of Alzheimer’s disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up

  2016cited by this paper
• The incidence of post-mortem neurodegenerative and cerebrovascular pathology in mixed dementia.

  2016cited by this paper
• A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease in Belgium

  2016cited by this paper
• Pathological α-synuclein distribution in subjects with coincident Alzheimer’s and Lewy body pathology

  2016cited by this paper
• Round robin test on quantification of amyloid‐β 1–42 in cerebrospinal fluid by mass spectrometry

  2016cited by this paper
• Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements

  2016cited by this paper
• The amyloid hypothesis of Alzheimer's disease at 25 years

  2016cited by this paper
• Amyloid-β Oligomers Relate to Cognitive Decline in Alzheimer's Disease

  2015cited by this paper
• Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis

  2015cited by this paper
• Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-β Isoforms for Early and Differential Dementia Diagnosis

  2015cited by this paper
• Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study

  2015cited by this paper
• Cerebrospinal Fluid β-Amyloid1–42 Levels in the Differential Diagnosis of Alzheimer’s Disease—Systematic Review and Meta-Analysis

  2015cited by this paper
• Clinical utility and applicability of biomarker-based diagnostic criteria for Alzheimer’s disease: a BeDeCo survey

  2015cited by this paper
• An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease.

  2015cited by this paper
• Overdiagnosing Vascular Dementia using Structural Brain Imaging for Dementia Work-Up

  2015cited by this paper
• Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid.

  2015cited by this paper
• Assessment of CSF Aβ42 as an aid to discriminating Alzheimer's disease from other dementias and mild cognitive impairment: a meta-analysis of 50 studies.

  2014cited by this paper
• Relationship Between β-Secretase, Inflammation and Core Cerebrospinal Fluid Biomarkers for Alzheimer's Disease

  2014cited by this paper
• Cerebrovascular Biomarker Profile Is Related to White Matter Disease and Ventricular Dilation in a LADIS Substudy

  2014cited by this paper
• Cerebrospinal Fluid Biomarker and Brain Biopsy Findings in Idiopathic Normal Pressure Hydrocephalus

  2014cited by this paper
• Qualification of a Surrogate Matrix-Based Absolute Quantification Method for Amyloid-β42 in Human Cerebrospinal Fluid Using 2D UPLC-Tandem Mass Spectrometry

  2014cited by this paper
• Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.

  2014cited by this paper
• A Selected Reaction Monitoring (SRM)-Based Method for Absolute Quantification of Aβ38, Aβ40, and Aβ42 in Cerebrospinal Fluid of Alzheimer's Disease Patients and Healthy Controls

  2013cited by this paper
• Amyloid Pathology Influences Aβ1-42 Cerebrospinal Fluid Levels in Dementia with Lewy Bodies

  2013cited by this paper
• Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease

  2013cited by this paper
• Soluble amyloid precursor protein α in the cerebrospinal fluid as a diagnostic and prognostic biomarker for idiopathic normal pressure hydrocephalus

  2013cited by this paper
• Idiopathic normal-pressure hydrocephalus

  2013cited by this paper
• Amyloid-beta isoform metabolism quantitation by stable isotope-labeled kinetics.

  2013cited by this paper
• Cerebrospinal Fluid Aβ1-40 Improves Differential Dementia Diagnosis in Patients with Intermediate P-tau181P Levels

  2013cited by this paper
• Aβ1-15/16 as a Potential Diagnostic Marker in Neurodegenerative Diseases

  2013cited by this paper
• Cerebrospinal fluid biomarkers in Alzheimer’s disease, vascular dementia and ischemic stroke patients: a critical analysis

  2013cited by this paper
• Evaluation of the Cerebrospinal Fluid Amyloid-β1-42/Amyloid-β1-40 Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders

  2013cited by this paper
• Performance of Aβ1-40, Aβ1-42, Total Tau, and Phosphorylated Tau as Predictors of Dementia in a Cohort of Patients with Mild Cognitive Impairment

  2012cited by this paper
• Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study.

  2012cited by this paper
• Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia

  2012cited by this paper
• Aminoterminally Truncated and Oxidized Amyloid-β Peptides in the Cerebrospinal Fluid of Alzheimer's Disease Patients

  2012cited by this paper
• Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms.

  2012cited by this paper
• Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.

  2012cited by this paper
• Different CSF β-amyloid processing in Alzheimer’s and Creutzfeldt–Jakob disease

  2011cited by this paper
• Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Cerebrospinal Fluid Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Combination with Subcortical and Cortical Biomarkers in Vascular Dementia and Alzheimer's Disease

  2011cited by this paper
• Decreased sAβPPβ, Aβ38, and Aβ40 Cerebrospinal Fluid Levels in Frontotemporal Dementia

  2011cited by this paper
• The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

  2011cited by this paper
• CSF Amyloid-β Peptides in Neuropathologically Diagnosed Dementia with Lewy Bodies and Alzheimer's Disease

  2011cited by this paper
• Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid

  2010cited by this paper
• Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease

  2010cited by this paper
• The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.

  2010cited by this paper
• Cerebrospinal Fluid Tau, p-Tau 181 and Amyloid-β38/40/42 in Frontotemporal Dementias and Primary Progressive Aphasias

  2010cited by this paper
• Added diagnostic value of CSF biomarkers in differential dementia diagnosis.

  2010cited by this paper
• Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid

  2010cited by this paper
• Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study

  2010cited by this paper
• High‐molecular‐weight β‐amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients

  2010cited by this paper
• CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies

  2010cited by this paper
• Thinking Outside the Box: Alzheimer-Type Neuropathology That Does Not Map Directly Onto Current Consensus Recommendations

  2010cited by this paper
• Subcortical Vascular Dementia Biomarker Pattern in Mild Cognitive Impairment

  2009cited by this paper
• Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

  2009cited by this paper
• No correlation between time-linked plasma and CSF Abeta levels.

  2009cited by this paper
• Clinicopathological concordance in dementia diagnostics.

  2009cited by this paper
• Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia.

  2008cited by this paper
• Prediction of Alzheimer’s Disease Using the CSF Aβ42/Aβ40 Ratio in Patients with Mild Cognitive Impairment

  2007cited by this paper
• Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementias

  2007cited by this paper
• Aspects of beta-amyloid as a biomarker for Alzheimer's disease.

  2007cited by this paper
• Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans

  2006cited by this paper
• Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry.

  2006cited by this paper
• CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia

  2006cited by this paper
• An Alzheimer's disease-specific β-amyloid fragment signature in cerebrospinal fluid

  2006cited by this paper
• Decreased cerebrospinal fluid amyloid beta (1–40) levels in frontotemporal lobar degeneration

  2006cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.

  2003cited by this paper
• CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study

  2003cited by this paper
• Phases of Aβ-deposition in the human brain and its relevance for the development of AD

  2002cited by this paper
• Hyperphosphorylation induces self-assembly of τ into tangles of paired helical filaments/straight filaments

  2001cited by this paper
• Plasma and cerebrospinal fluid Levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease

  2000cited by this paper
• Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.

  2000cited by this paper
• Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

  2000cited by this paper
• CSF levels of tau, β-amyloid1–42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging

  2000cited by this paper
• Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease.

  1998cited by this paper
• Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in Japan

  1998cited by this paper
• Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

  1998cited by this paper
• Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease'

  1998cited by this paper
• Combination assay of CSF Tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease

  1998cited by this paper
• Amyloid β-Peptide Is Transported on Lipoproteins and Albumin in Human Plasma*

  1996cited by this paper
• The profile of soluble amyloid beta protein in cultured cell media. Detection and quantification of amyloid beta protein and variants by immunoprecipitation-mass spectrometry.

  1996cited by this paper
• Rapid Communication: Characterization of β‐Amyloid Peptide from Human Cerebrospinal Fluid

  1993cited by this paper
• Characterization of beta-amyloid peptide from human cerebrospinal fluid.

  1993cited by this paper
• The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease.

  1993cited by this paper
• Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs.

  1992cited by this paper
• Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.

  1986cited by this paper
• Amyloid plaque core protein in Alzheimer disease and Down syndrome.

  1985cited by this paper

• Fe3O4@MoS2@Au-Ag microsphere-based ultrasensitive immunobiosensor for the early diagnosis of Alzheimer's disease.

  2025cites this paper
• Nanosensor-Driven Detection of Neuron-Derived Exosomal Aβ42 with Graphene Electrolyte-Gated Transistor for Alzheimer's Disease Diagnosis.

  2023cites this paper
• Racemization in Post-Translational Modifications Relevance to Protein Aging, Aggregation and Neurodegeneration: Tip of the Iceberg

  2021cites this paper
• Recent Electrokinetic and Microfluidic Strategies for Detection of Amyloid Beta Peptide Biomarkers: Towards Molecular Diagnosis of Alzheimer's Disease

  2020cites this paper
• Validation of the Erlangen Score Algorithm for Differential Dementia Diagnosis in Autopsy-Confirmed Subjects

  2019cites this paper
• Antibody-free detection of amyloid beta peptides biomarkers in cerebrospinal fluid using capillary isotachophoresis coupled with mass spectrometry.

  2019cites this paper
• Online Preconcentration in Capillaries by Multiple Large-Volume Sample Stacking: An Alternative to Immunoassays for Quantification of Amyloid Beta Peptides Biomarkers in Cerebrospinal Fluid.

  2018cites this paper
• Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer’s Disease Diagnosis

  2018cites this paper
• Mass spectrometry is a multifaceted weapon to be used in the battle against Alzheimer's disease: Amyloid beta peptides and beyond.

  2018cites this paper
• A review of biomarkers of Alzheimer's disease in noninvasive samples.

  2018cites this paper
• (−)Epigallocatechin-3-gallate attenuates anesthesia-induced memory deficit in young mice via modulation of nitric oxide expression

  2018cites this paper
• Amyloid β42 peptide is toxic to non-neural cells in Drosophila yielding a characteristic metabolite profile and the effect can be suppressed by PI3K

  2017cites this paper